These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11023772)

  • 1. Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.
    Neau D; Schvoerer E; Robert D; Dubois F; Dutronc H; Fleury HJ; Ragnaud JM
    J Infect; 2000 Sep; 41(2):192-4. PubMed ID: 11023772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
    Bessesen M; Ives D; Condreay L; Lawrence S; Sherman KE
    Clin Infect Dis; 1999 May; 28(5):1032-5. PubMed ID: 10452630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J; Bani-Sadr F; Gassin M; Raffi F
    Clin Infect Dis; 2001 Mar; 32(6):963-9. PubMed ID: 11247719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
    Benhamou Y; Bochet M; Thibault V; Di Martino V; Caumes E; Bricaire F; Opolon P; Katlama C; Poynard T
    Hepatology; 1999 Nov; 30(5):1302-6. PubMed ID: 10534354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
    Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
    J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
    Revill PA; Littlejohn M; Ayres A; Yuen L; Colledge D; Bartholomeusz A; Sasaduesz J; Lewin SR; Dore GJ; Matthews GV; Thio CL; Locarnini SA
    AIDS; 2007 Aug; 21(13):1701-10. PubMed ID: 17690567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
    Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
    J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
    Treviño A; Soriano V; Madejon A; Rodriguez C; Barros C; Botecchia M; Tuma P; Del Romero J; de Mendoza C
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1273-6. PubMed ID: 20001517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW; Hahm KB; Kim JH
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
    Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
    Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
    Rey D; Fritsch S; Schmitt C; Partisani M; Kempf-Durepaire G; Nicolle M; Krantz V; De Mautort E; Stoll-Keller F; Lang JM
    Gastroenterol Clin Biol; 2000 Jan; 24(1):125-7. PubMed ID: 10679599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.